A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours

Anti-Cancer Drugs

Volumn 14, Issue SUPPL. 1, 2003, Pages

  Hainsworth, John ^a   Vergote, Ignace ^b   Janssens, Jacques ^c  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Salvator Hospital   (Belgium)

Author keywords

Breast cancer; Non small cell lung cancer; Ovarian cancer; Treatment refractory; ZD9331

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; FOLIC ACID ANTAGONIST; PACLITAXEL; PLATINUM; PLEVITREXED;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APHASIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BRAIN EDEMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONFUSION; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; DRUG TRANSPORT; DYSPNEA; EPISTAXIS; FEVER; HUMAN; HYPOTENSION; ILEUS; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MELENA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; SEPSIS; SOLID TUMOR; SYNCOPE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0042126769     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200305001-00003     Document Type: Review

References (18)

1. Jemal A, Thomas A, Murrary T, Thun M. Cancer Statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
2. American Cancer Society. Cancer Facts and Figures 2002. http://www.cancer.org.
3. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38:99-166.
4. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 59 (suppl 4):9-17.
5. Conte PF, Cianci C, Tanganelli L, et al. Ovarian cancer: optimal chemotherapy in relapsed disease. Ann Oncol 2000; 11 (suppl 3):145-150.
6. Sirotnak FM. Obligate genetic expression in tumor cells of a fetal membrane property mediating 'folate' transport: biological significance and implications for improved therapy of human cancer. Cancer Res 1985; 45:3992-4000.
7. Jackman AL, Kimbell R, Brunton L, et al. Activity of ZD1694 and ZD9331 in human colon and ovarian tumour cell lines. Proc Am Ass Cancer Res 1996; 37:382.
8. Bertucci D, Smith R, Mani S, et al. A fixed dose phase I study of ZD9331, a novel non-polyglutamated inhibitor of thymidylate synthase in patients with refractory cancer. Eur J Cancer 1999; 35:S286.
9. Plummer R, Rees C, Judson I, et al. Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks. Eur J Cancer 1999; 35:S285.
10. Rees C, Beale P, Trigo J, et al. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase (TS) inhibitor given as a 5-day continuous infusion. Proc Am Soc Clin Oncol 1999; 18:657.
11. Trigo J, Rees C, Beale P, et al. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks. Eur J Cancer 1999; 35:S286.
12. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-2362.
13. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
14. Rader J, Clarke-Pearson D, Moore M, et al. Phase II trial of ZD9331 as third-line therapy for patients with ovarian carcinoma. Ann Oncol 2000; 11 (suppl 4):83 (abstr 368).
15. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16:334-352.
16. Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998; 16:2233-2237.
17. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18:1062-1067.
18. Brodowicz T, Koestler WJ, Tomek S, et al. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistance metastatic breast cancer. Anti-Cancer Drugs 2000; 11:149-153.